Sign inJoin waitlistJoin the waitlist

Celalettin Ustun

Section Chief, Bone Marrow and Stem Cell Transplant · Rush University Medical Center

Credentials: · · · · ·

History

Bone Marrow and Stem Cell Transplant Section · Rush University Medical Center
Present
Rush University Medical Center
Present
Rush University Medical Center
Present

Medical College of Georgia
1993–1994
Internal Medicine
Brody School of Medicine at East Carolina University
1990–1993
ANKARA UNIV, ANKARA
1986–1990

Research

Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML
New England Journal of Medicine · 2019 · 1,078 citations
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
The Lancet Oncology · 2017 · 424 citations
First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation
Blood · 2018 · 345 citations

Daniel Weisdorf
70 papers
EW
Erica Warlick
29 papers
BS
Bipin Savani
27 papers
Wael Saber
27 papers
Mark Litzow
25 papers
Claudio Brunstein
24 papers
Hillard Lazarus
24 papers
Sunita Nathan
24 papers
BW
Baldeep Wirk
22 papers
Cem Akin
22 papers
Jason Gotlib
22 papers
NB
Nelli Bejanyan
22 papers

Clinical trials

Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2027